



## **Warrants of series TO3 were subscribed to approximately 93.4 percent and Alzinova receives approximately SEK 26.3 million**

**Alzinova AB ("Alzinova" or the "Company") today announces the outcome of the exercise of warrants of series TO3 (the "Warrants"). In total, 12,112,231 Warrants were exercised, corresponding to approximately 93.4 percent of the total number of outstanding Warrants, for subscription of 12,112,231 shares at a subscription price of SEK 2.17 per share. Alzinova will receive approximately SEK 26.3 million before issuing costs through the exercise of the Warrants.**

The exercise period for exercise of the Warrants took place from and including April 11, 2023, up to and including April 25, 2023. The subscription price per share for exercising the Warrants was set to SEK 2.17.

In total, 12,112,231 Warrants were exercised for subscription of 12,112,231 shares, meaning that approximately 93.4 percent of all outstanding Warrants were exercised.

Exercised Warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately three (3) weeks.

### **Share capital and dilution**

Through the exercise of the Warrants, the number of shares in Alzinova increases by 12,112,231 shares, from 32,419,034 shares to a total of 44,531,265 shares. The share capital will increase by SEK 3,185,516.753 from SEK 8,526,205.942 to SEK 11,711,722.695.

For existing shareholders who did not exercise any Warrants, the dilution amounts to approximately 27.2 percent of the number of shares and votes in the Company.

*"A big thank you to all of you who subscribed for shares in this warrant program. It is gratifying to see a subscription rate of over 90% in the current market climate as evidence of your interest and trust in Alzinova! Through the capital injection of approximately SEK 26 million, we can continue the development of the vaccine ALZ-101 and the antibody ALZ-201 and take these further with the end goal of developing a new generation of Alzheimer's drugs. We are convinced that our candidates can make a big difference in future treatments for Alzheimer's disease." - Kristina Torfgård, CEO of Alzinova*

### **Advisers**

Mangold Fondkommission AB is the financial adviser, Fredersen Advokatbyrå AB is the legal adviser and Shark Communication is the communication adviser to the Company in connection with the exercise of the Warrants.



**For questions regarding the Warrants, please contact:**

Mangold Fondkommission AB  
E-mail: [emissioner@mangold.se](mailto:emissioner@mangold.se)

**For more information, please contact:**

Kristina Torfgård, CEO  
Tel. +46 708 46 79 75  
E-mail: [kristina.torfgard@alzinova.com](mailto:kristina.torfgard@alzinova.com)

*Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.*

**About Alzinova**

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A $\beta$ CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: [www.alzinova.com](http://www.alzinova.com)

**Attachments**

**Warrants of series TO3 were subscribed to approximately 93.4 percent and Alzinova receives approximately SEK 26.3 million**